Navigation Links
EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease
Date:7/15/2009

VIENNA, July 15 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the successful completion of a phase Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability and safety.

The announcement came at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria where EnVivo presented its findings. EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognitive dysfunction associated with Alzheimer's disease and schizophrenia.

"EVP-6124 appears to be safe and was well tolerated over a month of dosing," commented Kees Been, CEO of EnVivo. "Most excitingly, the cognition improvement was observed on top of the effect of acetylcholinesterase inhibitors the patients were already taking. This is a strong indicator of a biologic and potentially useful clinical effect."

In this Phase Ib/IIa safety and biomarker study in patients with mild to moderate Alzheimer's disease already taking chronic acetylcholinesterase inhibitor (AChEI) therapy (donepezil or rivastigmine), three separate doses of EVP-6124 or a placebo dose were administered to a total of 48 subjects for 28 days. Safety and tolerability were determined by adverse events, clinical assessments, and laboratory studies. Cognition in AD patients was measured using the computerized CogState battery system and a group of traditional 'paper and pencil' cognition tests.

Minimal treatment-emergent adverse effects were observed during the trial and there were no serious adverse events. Improvement in a number of cognition measures in EVP-6124 treated patients were observed compared to placebo treated patients. These included measures of attention, verbal and language fluency,
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. EnVivo Pharmaceuticals Announces Executive Appointment
2. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Graphite Metallizing Corporation announces a ... in stainless steel pillow blocks. This series combines ... the application and installation versatility of pillow blocks. ... work exceptionally well when submerged in water, water-soluble ... as acids, alkalies, hydrocarbons, black liquor, and liquid ...
(Date:5/23/2013)... -- Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a ... and therapeutics, announced today that StemCyte has become an ... car driven by James Jakes . ... 2013 season.   StemCyte, Inc. and Rahal Letterman ... umbilical cord blood banking and its educational initiative ,Stars ...
(Date:5/23/2013)... 2013 VG Energy, an agricultural biotech ... Renewable Research to conduct field trials using LipidMax ... is a majority owned subsidiary of VG Life ... Energy,s exclusively licensed compound LipidMax selectively inhibits certain ... plants, possessing a wide variety of applications including ...
(Date:5/23/2013)... May 23, 2013 BioTrends Research Group, ... firms for specialized biopharmaceutical issues, finds that, unaided, ... disease specialists reported that in the past six ... delaying treatment) in anticipation of the next generation ... ago, when only 6 percent reported that they ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... capital for clinical trials, ZyStor Therapeutics will be ... venture capital forum next month in Overland Park, Kan. ... like to raise an additional $15 million or more in ... begin in early 2008. , ,The company, located in ...
... - During a meeting with U.S. Health and ... Wisconsin employers and healthcare organizations pledged to support health ... in the health information technology products used by their ... of an effort to support a national initiative aimed ...
... that a return to profitability won't happen until later this ... of $258.5 million, or $7.67 per diluted share, in a ... of financial reporting errors. , ,The loss, which included a ... million, or $6.85 per share, compares to a net loss ...
Cached Biology Technology:ZyStor seeks to raise $15M for clinical trials 2ZyStor seeks to raise $15M for clinical trials 3Wisconsin firms pledge to support healthcare IT standards 2Merge Healthcare suffers $258M loss in `06 2
(Date:5/23/2013)... of Public Health at Emory University, along with ... received a $4 million grant over four years ... (Health and Exposome Research Center: Understanding Lifetime Exposures). ... awarded in the United States. , The ... of Environmental Health Sciences (NIEHS) of the National ...
(Date:5/23/2013)... 2013) A new report from the Institute of ... engage in at least 60 minutes of vigorous or ... more than half of American youth meet current evidence-based ... moderate intensity physical activity daily, according to the report, ... in school for nearly half of their waking hours, ...
(Date:5/23/2013)... when microbial pathogens are growing increasingly resistant to the ... of Wisconsin scientists has synthesized a potent new class ... staph infections. , Writing online in the Journal ... by University of Wisconsin-Madison chemistry Professor Helen Blackwell describes ... of Staphylococcus aureus , a bacterium at the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide students with daily physical activity, IOM recommends 2University of Wisconsin chemists find new compounds to curb staph infection 2
... release is available in German . ... that are crucial in fighting pathogen assault. Researchers ... the Helmholtz Centre for Environmental Research (UFZ) characterized ... class II locus in a tailed amphibian. Unlike ...
... Manchester has been successful in gaining major European ... millions of biological samples, such as DNA, can ... across Europe. The Centre for Integrated Genomic ... Translational Medicine, is playing a key role in ...
... CA Nitrogen is essential to all life on Earth, and ... determine how ecosystems respond to global warming. But certain aspects ... puzzled scientists, defying, in a sense, the laws of supply ... atmosphere often thrive where it is readily available in the ...
Cached Biology News:New findings on immune system in amphibians 2Manchester clears first hurdle in €170 million biobank building boom 2Researchers explain nitrogen paradox in forests 2